Pertuzumab + Trastuzumab [Phesgo]

[MSHL] Pertuzumab + Trastuzumab Fixed Dose Combination Injection 1,200 mg/600 mg, 600 mg/600 mg

1. Fixed-dose pertuzumab and trastuzumab subcutaneous injection in combination with chemotherapy for treating HER2-positive metastatic or locally recurrent breast cancer, in patients without prior treatment for metastatic disease. Treatment with pertuzumab should be stopped if disease progresses.

2. Fixed-dose pertuzumab and trastuzumab subcutaneous injection in combination with chemotherapy for adjuvant treatment of high-risk (with positive nodes) HER2-positive early breast cancer for a maximum duration of 1 year.

3. Fixed-dose pertuzumab and trastuzumab subcutaneous injection in combination with chemotherapy for neoadjuvant treatment of HER2-positive locally advanced, inflammatory or early stage (tumour >2 cm in diameter or node positive) breast cancer for 4 to 6 cycles. Following surgery, patients may continue with trastuzumab with or without pertuzumab for a total of 1 year of anti-HER2 treatment.

Legend

This section shows the following:

• Subsidy Scheme and Clinical Indication (where applicable) of drugs listed in the MOH List of Subsidised Drugs

• Subsidised brands of vaccines recommended in the National Immunisation Schedules listed in the MOH Subsidised Vaccine List

• Cancer Drug and Clinical Indication listed in the MediShield Life Cancer Drug List

As this website is updated monthly, please refer to MOH List of Subsidised Drugs, MOH Subsidised Vaccine List or MediShield Life Cancer Drug List for the most updated information.

01/09/2023 Review of cancer drugs for treating early or advanced HER2-positive breast cancer

[NR] The Ministry of Health’s Drug Advisory Committee has not recommended listing pertuzumab, pertuzumab plus trastuzumab fixed-dose subcutaneous (SC) injection, trastuzumab emtansine or tucatinib on the Medication Assistance Fund (MAF) for treating human epidermal growth factor receptor (HER2)-positive breast cancer due to unfavourable cost-effectiveness at the prices proposed by the manufacturer.

Clinical indications, subsidy class and MediShield Life claim limits for all drugs included in the evaluation are provided in the Annex.

Legend

This section displays recommendation from the MOH Drug Advisory Committee for subsidy and appropriate use of the drug as extracted from the Agency for Care Effectiveness (ACE) Drug Guidances. As this website is updated monthly, please refer to the ACE website for the most updated information.

Note:

General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.

Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration